Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bioburden Reduction of Diabetic Foot Ulcer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2008 by Nomir Medical Technologies.
Recruitment status was  Not yet recruiting
Information provided by:
Nomir Medical Technologies Identifier:
First received: October 18, 2008
Last updated: October 20, 2008
Last verified: October 2008
Study to see if a laser can get rid of bacateria called MRSA in your diabetic ulcer

Condition Intervention Phase
Diabetic Foot Ulcer
Device: Noveon laser
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Noveon Laser Treatment to Effect Bioburden Reduction or Elimination in Diabetic Foot Ulcer: A Davice Performance Clinical Study

Resource links provided by NLM:

Further study details as provided by Nomir Medical Technologies:

Primary Outcome Measures:
  • Decrease of Bioburden Effect In diabetic Foot Ulcer [ Time Frame: 28 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: November 2008
Estimated Study Completion Date: November 2009
Estimated Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Noveon laser
    870 and 930nm wavelengths

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 and older
  • Diabetic foot ulcer
  • MRSA positive

Exclusion Criteria:osteomylelitis pregnancy allery to e mycin

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00776854

Contact: Alan Robbins, MD 781-893-1000

United States, Massachusetts
Nomir Medical Not yet recruiting
Waltham, Massachusetts, United States, 02452
Contact: Alan robbins, MD    781-893-1000      
Sponsors and Collaborators
Nomir Medical Technologies
  More Information

Responsible Party: Alan Robbin, M.D., Nomir Medical Identifier: NCT00776854     History of Changes
Other Study ID Numbers: 12.001a 
Study First Received: October 18, 2008
Last Updated: October 20, 2008
Health Authority: United Stated: Institutional Review Board

Additional relevant MeSH terms:
Diabetic Foot
Foot Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases processed this record on October 25, 2016